Biophytis (EPA:ALBPS) | WebDisclosure

PRESS RELEASE

published on 06/12/2024 at 10:11, 1 year 10 months ago

Biophytis annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens
Biophytis annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens. La société se focalise sur le traitement de maladies liées à l'âge, notamment la Dystrophie Musculaire de Duchenne

Biophytis BIO101 Seqens Transfert Industriel DMD
PRESS RELEASE

published on 06/12/2024 at 10:11, 1 year 10 months ago

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis successfully transfers BIO101 (20-hydroxyecdysone) production to industrial scale with Seqens, enhancing therapeutic solutions for Duchenne Muscular Dystrophy patients

Biophytis Duchenne Muscular Dystrophy BIO101 Seqens 20-hydroxyecdysone
BRIEF

published on 06/12/2024 at 07:05, 1 year 10 months ago

Biophytis annonce le succès du transfert de production de BIO101 par Seqens

Biophytis Dystrophie Musculaire De Duchenne BIO101 Seqens Production Industrielle
BRIEF

published on 06/12/2024 at 07:05, 1 year 10 months ago

Biophytis Announces Successful Industrial Transfer of BIO101 Production by Seqens

Biophytis Clinical Trial Duchenne Muscular Dystrophy BIO101 Seqens
REGULATED PRESS RELEASE

published on 06/12/2024 at 07:00, 1 year 10 months ago

Biophytis annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens
Biophytis annonce le succès du transfert industriel de production de BIO101 par Seqens, renforçant ainsi son programme de développement clinique pour traiter la Dystrophie Musculaire de Duchenne (DMD)

Biophytis Dystrophie Musculaire De Duchenne BIO101 Seqens Transfert Industriel
REGULATED PRESS RELEASE

published on 06/12/2024 at 07:00, 1 year 10 months ago

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis announces successful industrial transfer of BIO101 (20-hydroxyecdysone) production by Seqens for DMD treatment. Collaboration strengthens therapeutic solutions and accelerates clinical programs

Biophytis Clinical Development Duchenne Muscular Dystrophy BIO101 Seqens
BRIEF

published on 06/10/2024 at 08:23, 1 year 10 months ago

Biophytis dépose une demande d'IND pour une étude de phase 2 dans l'obésité

Biophytis Phase 2 BIO101 Obésité IND
BRIEF

published on 06/10/2024 at 08:23, 1 year 10 months ago

Biophytis Files IND Application for Phase 2 Obesity Study with US FDA

FDA Biophytis Clinical Study Obesity IND Application
BRIEF

published on 06/10/2024 at 08:21, 1 year 10 months ago

Biophytis dépose une demande d'IND pour une étude de phase 2 dans l'obésité

FDA Biophytis Phase 2 BIO101 Obésité
BRIEF

published on 06/10/2024 at 08:21, 1 year 10 months ago

Biophytis files IND application for phase 2 study in obesity

FDA Biophytis Phase 2 BIO101 Obesity

Published on 05/09/2026 at 01:55, 16 hours 21 minutes ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 16 hours 36 minutes ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 16 hours 46 minutes ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 18 hours 16 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 19 hours 15 minutes ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

Published on 05/08/2026 at 20:38, 21 hours 38 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 23 hours 3 minutes ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 23 hours 14 minutes ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 23 hours 47 minutes ago

Designated Person Notification
Published on 05/08/2026 at 18:29, 23 hours 47 minutes ago

Designated Person Notification

View all EQS

Published on 05/07/2026 at 19:15, 1 day 23 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 23 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 23 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 23 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 23 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE

News